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timing of kidney failure requiring KRT was also developed.
The implications of these ﬁndings for patient management
were discussed in the context of published evidence under
4 key themes: management of CKD G4D, diagnostic and
therapeutic challenges of heart failure, shared decision-
making, and optimization of clinical trials in CKD G4D
patients. Participants concluded that variable prognosis of
patients with advanced CKD mandates individualized, risk-
based management, factoring in competing risks and
patient preferences.
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C hronic kidney disease (CKD), deﬁned by persistentreduction in glomerular ﬁltration rate (GFR) and/orthe presence of other signs of kidney damage, is clas-
siﬁed based on GFR and albuminuria categories.1 The risk for
adverse outcomes, including mortality and kidney failure,
increases with decreasing GFR and increasing albuminuria.2
Individuals with a GFR below 30 ml/min per 1.73 m2 (i.e.,
CKD G4 or G5) are at particularly high risk across all1
KDIGO execu t i ve conc lu s i ons K-U Eckardt et al.: Prognosis of advanced CKD: a KDIGO conference reportalbuminuria categories (Figure 1). In addition, CKD-speciﬁc
complications increase markedly at low levels of GFR, with
cardiovascular disease (CVD) being a leading cause of
morbidity and mortality. Of particular relevance is heart
failure (HF), one of the most common CVD conditions for
patients with CKD G4 or higher.
Kidney replacement therapy (KRT; i.e., dialysis or trans-
plantation) can mitigate the consequences of kidney failure
and improve prognosis. However, there are large variations in
incidence rates of KRT3, and globally only approximately half
of those with kidney failure receive KRT.4 Inequalities in ac-
cess to KRT play an important role, but differences in practice
patterns also exist. There is agreement that level of GFR alone
should not be used as a trigger for KRT initiation, and that
signs and symptoms associated with kidney failure should be
considered. Nevertheless, deﬁning the optimal time for KRT
initiation remains a challenge.1 Importantly the ﬁrst few
months on dialysis have been identiﬁed as a very high-risk
period, though it remains unknown to what extent adverse
events are triggered by dialysis initiation.5,6 Referral to
nephrology services shortly before dialysis initiation has been
associated with an increased risk of adverse outcomes as
compared with earlier referral.7,8
Thus, low GFR (<30 ml/min per 1.73 m2) corresponding
to CKD G4 or G5 (excluding patients on KRT and referred to
subsequently as “CKD G4þ”) reﬂects a critical state for pa-
tients. A better understanding of prognosis of patients withFigure 1 | Schematic presentation of chronic kidney disease
(CKD) categories and conference focus. Per deﬁnition, CKD G5
includes patients with kidney failure with and without kidney
replacement therapy (KRT). The conference focus (dashed line) was
on patients within glomerular ﬁltration rate (GFR) categories G4 and
G5, excluding individuals already on KRT, but including KRT as an
important end point. D ¼ patients on dialysis therapy, T ¼ patients
with a kidney transplant. Colors reﬂect different risk categories for
adverse outcomes as compared with individuals without CKD:
green ¼ no increase in risk; yellow ¼ slightly elevated risk;
orange ¼ moderately elevated risk; and red ¼ severely elevated risk.
Adapted with permission from Kidney Disease: Improving Global
Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice
Guideline for the Evaluation and Management of Chronic Kidney
Disease. Kidney Int Suppl. 2013;3:1–150.1
2CKD G4þ may inform treatment strategies, including
decision-making for initiation of KRT. Therefore, Kidney
Disease: Improving Global Outcomes (KDIGO) collaborated
with the CKD Prognosis Consortium (CKD-PC) to initiate a
global meta-analysis of cohort studies (population-based
cohorts, referred CKD cohorts, and research cohorts). The
primary aim was to determine the prognosis of patients with
advanced CKD with respect to initiation of KRT, CVD events,
mortality, and relative timing of these events,9 with a second
aim to determine variability of patient prognosis according to
cohort, demographic, or health characteristics.10
The results from the global meta-analysis were presented
to an international expert group at a KDIGO Controversies
Conference in December 2016, and implications for patient
management were discussed. Breakout groups focused on: (i)
management of CKD G4þ, (ii) diagnostic and therapeutic
challenges of HF in CKD G4þ, (iii) shared decision-making
for KRT initiation, and (iv) optimization of clinical trials in
CKD G4þ patients. To curtail the scope of the conference,
speciﬁc aspects of children and patients with a failing trans-
plant were not addressed.
We present here a summary of the discussion and main
conference conclusions with respect to management and
future research in patients with CKD G4þ. Detailed pre-
sentations of the meta-analysis are published in the com-
panion papers.9,10
Prognosis of patients with CKD G4D: novel insights from a
global meta-analysis of cohort studies
In preparation for the conference, we conducted a global
meta-analysis with the goal of examining absolute and relative
risks of outcomes in a large, diverse population of patients
with CKD stage G4þ. The meta-analysis of risk factors for
KRT, CVD events, and death included 28 cohorts (n ¼
185,024) using standard survival analysis and Cox regres-
sion.10 The risk prediction meta-analysis included 29 cohorts
(n ¼ 264,296).9
The main ﬁndings included that established risk factors for
CVD were highly relevant in CKD G4þ patients, but their
relative importance differed by outcome (Figure 2). Age and
history of CVD were negatively related to risk of KRT but
positively related to CVD and death risk. Current smoking
was most strongly associated with death. Blood pressure was
positively associated with KRT risk but showed a U-shaped
association with CVD and mortality. Diabetes and male sex
were risk factors for all outcomes but strongest for CVD and
KRT, respectively. Black race was only positively related to
KRT. Lower estimated GFR (eGFR) and higher albumin-to-
creatinine ratio (ACR) were more strongly associated with
KRT than other outcomes. Finally, time-varying CVD events
and initiation of KRT were strongly associated with subse-
quent occurrence of death. The second meta-analysis focused
on the development of a new risk calculator for CVD events,
KRT and death, as diagramed in Supplementary Figure S1.9
The CKD G4þ risk calculator uses a pie chart format to
show the probability of all outcomes in a given follow-upKidney International (2018) -, -–-
Figure 2 | Hazard ratios for KRT, CVD events, and death associated with different variables. Colors indicate the strength of association,
from protective in green to strongly positive in red. Based on 19 cohorts with KRT, CVD, and death outcomes. Bold denotes statistically
signiﬁcant values. ACR, albumin-to-creatinine ratio; CI, conﬁdence interval; CVD, cardiovascular disease; eGFR, estimated glomerular ﬁltration
rate; KRT, kidney replacement therapy; SBP, systolic blood pressure. Adapted with permission from Evans M, Grams ME, Sang, Y, et al. Risk
factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. https://doi.org/10.1016/j.ekir.2018.01.002.10
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equation/). For example, as illustrated in Figure 3, at an eGFR
of 25 ml/min per 1.73 m2 and the covariates noted in the ﬁgure
legend, the proportion of participants predicted to receive KRT
within 4 years increases from 13% to 32% with increasing
albuminuria, while the risk of death increases from 22% to
30%. In the overall population examined who had a median
eGFR of 24 ml/min per 1.73 m2 and ACR of 168 mg/g, over
50% of participants were predicted to be event free at 4 years.
The predicted risk of remaining event free for 2 years
varies from less than 20% to greater than 80%, illustrating the
predictive power of measured patient characteristics.9
This CKD-PC global meta-analysis9 extends the estab-
lished kidney failure risk equation (KFRE) for prediction of
KRT11,12 as well as conﬁrms its value in CKD G4þ. Together
with the KFRE, the new CKD G4þ risk calculator provides
easily accessible tools to physicians, patients, and policy
makers that translate patient characteristics into powerful risk
discrimination. It is still important to keep in mind that
additional characteristics, often unmeasured, inﬂuence risk
further, and hence part of individualization should include
recognition of the limitations of quantitative risk estimates.Kidney International (2018) -, -–-Management of patients with CKD G4D
Risk-based assessment and management. People with
CKD G4þ are at risk for kidney failure, hospitalizations, CVD
events, death, and often under-recognized outcomes such as
disability, cognitive impairment, falls, and infection. The
KFRE equation11 and the new CKD G4þ risk calculator
provide useful tools in risk prediction, and their consistency
is reassuring. Other similar models have also been
published.13,14 Further reﬁnement including prediction of
additional patient-relevant outcomes remains an important
task for future research. Nevertheless, the available models
appear sufﬁcient to advocate for their implementation.
Incorporating patient preferences and values. There is
growing recognition that patients want to be involved as equal
partners in their care.15 Shared decision-making can lead to
productive interactions between patients, family, carers, and
health care providers, thus actively involving all partners in
treatment decisions, providing sufﬁcient education about
treatment options and their attributes, utilizing strategies to
elicit patients’ values, identifying patient preferences, and
achieving agreement about the course of treatment.16,17
Further work to develop and evaluate strategies and3
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Figure 3 | Example from the chronic kidney disease (CKD) G4D risk calculator. The probability and timing of adverse events at (upper
panel) 2 years and (lower panel) 4 years with increasing level of albuminuria. In these models, the scenario was set at age 60 years, male, white,
with a history of cardiovascular disease, not a current smoker, systolic blood pressure of 140 mm Hg, with diabetes, and an estimated
glomerular ﬁltration rate of 25 ml/min per 1.73 m2. ACR, albumin-to-creatinine ratio; CVD, cardiovascular disease; KRT, kidney replacement
therapy. For comparison, risk predictions for individuals with the same patient characteristics but no diabetes are presented in Grams ME, Sang
Y, Ballew SH, et al. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular ﬁltration
rate. Kidney Int. https://doi.org/10.1016/j.kint.2018.01.009.9
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required to achieve these goals.
Models of care. So far, data on the systematic imple-
mentation of models of care for people with CKD G4þ are
relatively sparse, and the relationships between speciﬁc ele-
ments of CKD care and patient outcomes remain to be
determined. Nevertheless a number of overarching consid-
erations appear valid (Table 1), and speciﬁc stakeholder issues
should be considered (Supplementary Table S1). Moreover,
key competencies can be outlined that appear critical for
successful implementation of models of care (Supplementary
Table S2).
The potential beneﬁts of a multidisciplinary team
approach have been described over 20 years ago.18 A recent
systematic review (18 studies; 8853 patients) found that
multidisciplinary care of patients with CKD was associated
with lower risks of all-cause mortality, dialysis, and central
venous catheter use for dialysis access.19 Although initially4associations with improved outcomes have been limited to
observational studies and had not been borne out in ran-
domized trials,20 2 recent trials have reported encouraging
results. The ESCORT (Effectiveness of Integrated Care on
Delaying Progression of Stage 3-4 Chronic Kidney Disease in
Rural Communities of Thailand) study, a community-based,
cluster randomized controlled trial, reported signiﬁcant
delay in progression of CKD associated with improvements in
blood pressure and diabetes control and serum bicarbonate
with the introduction of an integrated CKD care program.21
In addition to routine care, comprehensive medical care
and education including advice on diet, exercise, and medi-
cation was provided as part of the intervention. In another
cluster randomized controlled trial, Lalonde and colleagues
introduced a training and communication network program
for pharmacists as part of the multidisciplinary care of people
with CKD in Quebec, Canada.22 In a cohort of patients
already beneﬁting from multidisciplinary care, theKidney International (2018) -, -–-
Table 1 | Ten points to consider within models of care for CKD
G4D
1. Patient-orientated care should be a key priority
2. Categorize CKD according to cause of kidney disease, level of GFR, and
degree of albuminuria
3. Estimate risk and prognosis and tailor management accordingly
4. Prevent CKD progression and avoid acute kidney injury where
possible
5. Evaluate and manage comorbid conditions, paying particular atten-
tion to ischemic heart disease, heart failure, and stroke prevention
6. Identify, prevent, and manage CKD-speciﬁc complications (e.g.,
malnutrition, anemia, bone disease, and acidosis)
7. Plan and prepare for treatment of kidney failure (e.g., choice of mo-
dality, access-placement and care, pre-emptive transplantation) and
provide conservative care and palliative care options where required
8. Ensure that psychosocial support is provided
9. Maintain continuity across transitions of care
10. Ensure that all communication channels are open: CKD care system to
patient and/or carer; between CKD team members; and between CKD
team and other health professionals
CKD, chronic kidney disease; GFR, glomerular ﬁltration rate.
Table 2 | Therapeutic uncertainties in CKD G4D management
1. How should we weigh the risks-beneﬁts of common medical and
surgical interventions in people with CKD G4þ, including blood
pressure and glycemic control, major surgery, and other medical
procedures or exposures? Do these vary by degree of albuminuria?
2. Should treatment goals, including blood pressure, be modiﬁed
dependent upon age and/or comorbidity?
3. Can we extrapolate recommended HbA1c targets to people with CKD
G4þ?
4. Should metformin treatment be discontinued in people with diabetes
and CKD G4þ?
5. Should we advise a restricted salt intake in people with CKD G4þ, and
if so what level of intake should we advise?
6. Should we advise modiﬁcation of dietary protein intake in people with
CKD G4þ? For example, should we advise more plant-based protein
intake?
7. Should we treat acidosis in people with CKD G4þ, and if so, at what
level of serum bicarbonate should treatment be initiated?
8. Should asymptomatic hyperuricemia be treated in people with CKD
G4þ, and if so, at what level of serum uric acid should treatment be
initiated?
9. Should aspirin for prevention of cardiovascular disease be continued
in people with CKD G4þ, or does the risk of bleeding outweigh po-
tential beneﬁts?
10. Do other cardiovascular disease prevention strategies convey the
same beneﬁts in people with CKD G4þ as compared with people with
less advanced CKD?
11. How can the risk of acute kidney injury in people with CKD G4þ be
mitigated? Should we advise tablet holidays during intercurrent
illness, and if so, what tablets should be temporarily discontinued and
for how long?
12. Are there subclinical events such as tubulointerstitial injury, inﬂam-
mation and ﬁbrosis, and unrecognized episodes of acute kidney injury
associated with CKD progression, and are these linked to short-lived
prescription of medicines or to nonprescription medication
exposures?
CKD, chronic kidney disease.
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cation use and reduced the number of drug-related problems
by 15%. It seems intuitive that access to multidisciplinary care
providers may be attractive to many patients; however, the
impact on patient experience and the optimal design and
involvement of team members still remains unclear.23 We
suggest that models of care should place patients at the center
of a transparent and open structure that ensures optimal
communication and use of available resources
(Supplementary Figure S2).
Additional research is needed to explore models that
address context-speciﬁc care in low- and middle-income
countries, multi-morbidity and integration of multidisci-
plinary care providers and other specialists around the pa-
tient; new technologies that can enhance communication
between stakeholders; and strategies to bridge transitions of
care between hospital and community, as well as between
phases of CKD, dialysis, and transplant care.
Uncertainties about targets and therapies. There are
important uncertainties in CKD G4þ management (Table 2).
In general these include interventions that are either targeting
the underlying kidney disease or aim at primary and sec-
ondary prevention of CVD complications. Frequently, evi-
dence has been extrapolated from studies in other stages of
CKD or younger age groups, or is based on observational
studies. For example, although some trials of renin-
angiotensin-aldosterone system (RAAS) blockage have
included patients with CKD G4þ,24 uncertainty remains
about generalizing its efﬁcacy to CKD G4þ patients.25 Results
of a trial designed to test the role of stopping treatment with
RAAS blockade to stabilize kidney function in patients with
progressive or late CKD G4þ are awaited.26 Current evidence
and guideline recommendations for several important ther-
apeutic areas are shown in Table S3. Given the high burden
and altered metabolism of drugs in CKD G4þ, exploration of
drug interactions and adverse medication safety events should
also be a priority.Kidney International (2018) -, -–-Research recommendations for management of patients
with CKD G4þ are summarized in Table 3.
Cardiovascular complications during CKD G4D: heart failure
A focus of management during CKD G4þ is on preventing
CVD, which remains one of the leading causes of morbidity
andmortality. HF is of special relevance for CKDG4þ patients
as it is one of the most common cardiovascular conditions, and
yet there remainmany diagnostic and therapeutic uncertainties
in the management of HF during CKD G4þ, particularly in
patients approaching the transition to KRT.
Deﬁnition, risk factors, and diagnosis of heart failure in CKD
G4þ. Patients with CKD have an elevated risk of HF27,28
that increases with severity of CKD.29 Among patients
receiving KRT, 40% have HF,30 with higher prevalence rates
among patients on hemodialysis compared with peritoneal
dialysis and kidney transplant recipients.31 The cumulative
incidence of HF is also high among patients with CKD and
those receiving KRT (Supplementary Figure S3).32
HF is deﬁned as a syndrome of inadequate ﬁlling and/or
pumping to meet systemic demands. There are 2 types of HF,
with preserved ejection fraction (HFpEF) and reduced ejec-
tion fraction (HFrEF), and deﬁning HF subtypes has been an
area of ongoing work by the ACCF/AHA33 and ESC345
Table 3 | Research recommendations for general
management of patients with CKD G4D
1. Risk-based assessment and management
Implementation and evaluation of prognostic models in clinical care to
guide risk-based management approaches. Researchers should
consider clinical impact analyses of tools that link prognostic
information on kidney failure to speciﬁc guidance for common CKD
management decisions and evaluate the impact on measures of
appropriateness, timeliness, patient-centeredness, and efﬁciency of CKD
care.
Derivation, validation, and impact analyses of prognostic models for
other outcomes in addition to kidney failure. In addition to CVD
events, kidney failure, and death, models should consider patient-
centered outcomes including quality of life, functional status, cognitive
impairment and hospitalization. Prognostic models that help patients
and providers weigh the relative beneﬁts and risk of common medical
therapies, radiologic procedures (e.g., angiography), and surgery for
patients with CKD should also be investigated.
2. Incorporating patient preferences and values
Development and evaluation of tools and resources to elicit patient
values and preferences for management options throughout CKD
G4þ. Such studies should evaluate the impact of tools to facilitate
shared decision-making on patient-reported outcomes and experience
measures, including measures of knowledge transfer and the quality of
decision-making processes in CKD management.
3. Models of care
Evaluation of the impact of clinic structures and processes on patient
experience, outcome measures, and costs of providing care. Speciﬁc
structural interventions that require further evaluation include ﬁnancial
incentives to support longitudinal patient care rather than episodic
health care contacts; novel strategies to address multi-morbidity;
technology-based strategies to enhance communication; and transition
of care interventions addressing gaps between hospital and
community, as well as between phases of pre-dialysis, dialysis, and
transplant care.
4. Uncertainties about targets and therapies
Evaluation of novel, emerging, and existing pharmacotherapeutic
strategies in randomized controlled trials speciﬁcally in populations
with CKD G4þ. Promising therapies include bicarbonate therapy and
treatment of asymptomatic hyperuricemia to slow progression in the
later stages of CKD, as well as aspirin for primary prevention of
cardiovascular events. Inclusion of patients with CKD G4þ should also
be a priority for future trials of blood pressure control, glycemic targets,
and comparative effectiveness studies of medication safety.
CKD, chronic kidney disease; CVD, cardiovascular disease.
Figure 4 | Unadjusted survival in patients with heart failure, by
chronic kidney disease (CKD) status, 2010 to 2011. Reproduced
from United States Renal Data System. 2015 USRDS annual data
report: Epidemiology of Kidney Disease in the United States. National
Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases, Bethesda, MD, 2015.Available at: www.usrds.org/2
013/pdf/v1_ch4_13.pdf.40 Accessed February 28, 2017.
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tients with CKD.35
Diagnosis of HF remains challenging in patients with
CKD, particularly in CKD G4þ, given the difﬁculty in dis-
tinguishing causes of volume overload. HF should be deﬁned
as the presence of HF symptoms and structural and/or
functional abnormalities on cardiac imaging (Supplementary
Table S4).33 In observational studies, imaging data are
frequently not available. In fact, in the CKD-PC analysis, HF
deﬁnitions were not sufﬁciently harmonized across cohorts to
allow a valid analysis of incidence rates and risk prediction.
Moreover, despite the recognized importance of HF, it re-
mains unknown whether screening for HF, either with im-
aging or cardiac biomarkers,36 leads to improved outcomes in
patients with CKD G4þ.6Traditional as well as novel risk factors, including meta-
bolic abnormalities, uremic toxins, and sympathetic over-
activity, accelerate the development of HF in patients with
CKD G4þ (Supplementary Table S5).37,38
Outcomes associated with heart failure in CKD G4þ. HF is
associated with poor outcomes in patients with CKD,
including greater risk of death, particularly in patients who
are older, have HFrEF (Supplementary Table S6),39,40 or have
severely decreased GFR (Figure 4). HF contributes signiﬁ-
cantly to morbidity among CKD patients, leading to frequent
hospitalizations and re-hospitalizations.41–44 HF is also asso-
ciated with episodes of acute kidney injury45 and progression
of CKD.46,47 Among incident dialysis patients, volume over-
load compared with other dialysis indications is associated
with the greatest risk of post-KRT mortality.48
Progression of clinical and subclinical heart failure after
initiation of dialysis. Only a few studies have evaluated lon-
gitudinal changes in subclinical HF, as assessed by echocar-
diograms, in patients with CKD G4þ, and the results are not
consistent. In the CRIC study, mean left ventricular mass index
did not change after the initiation of KRT. However, there was a
modest but statistically signiﬁcant decline in left ventricular
ejection fraction.49 The CASCADE study examined echocar-
diograms in patients with CKD G3þ50 and reported that left
ventricular mass index and left atrial volume both increased
within a year; however, the change in left ventricular ejection
fraction was not statistically signiﬁcant. In the IDEAL trial,
serial echocardiograms performed 12 months apart showed no
change in left ventricular mass index, left atrial diameter, dia-
stolic dysfunction, or left ventricular ejection fraction after
dialysis initiation.51 It should be noted, however, that in this
study, over 40% initiated peritoneal dialysis (PD) versus he-
modialysis (HD). In another study of 41 HF patients, left
ventricular mass index decreased after initiation of HD.52
Vascular access and heart failure. Vascular access prepa-
ration is a key component of management in CKD G4þ
patients. There are numerous postulated changes in the car-
diovascular system after creation of an arteriovenous ﬁstula53
(Supplementary Table S7). Small studies or case reports haveKidney International (2018) -, -–-
K-U Eckardt et al.: Prognosis of advanced CKD: a KDIGO conference report KD IGO execu t i ve conc lu s i onssuggested that arteriovenous ﬁstula may lead to development
of high-output HF.54–58 Arteriovenous ﬁstula creation has
also been reported in small studies to worsen right ventricular
hypertrophy and pulmonary hypertension54,59 and found to
be associated with signiﬁcant right ventricular dilatation and
remodeling and an increased risk for development of incident
heart failure.60 On the other hand, other studies found a
stabilization of kidney function after access creation.61 Larger
prospective studies are needed to understand optimal access
management in patients with CKD G4þ and HF.
Management of heart failure in CKD G4þ. Management of
HF in patients with CKD, particularly CKD G4þ, is
complicated (Table 4). Almost all HF trials have excluded
patients with advanced CKD, and few have been successful in
improving outcomes in patients with HFpEF. Post hoc ana-
lyses have included some patients with moderate CKD, but
suggest an attenuated effect of therapies such as b-blockers
and implantable cardioverter deﬁbrillators.62–64 In addition,
the presumed risk of hyperkalemia limits the use of RAAS
inhibitors and mineralocorticoid receptor antagonists in CKD
G4þ.44,65 Among patients receiving KRTwith known HF, the
proportion of patients with prescribed therapies such as
RAAS inhibitors and b-blockers remains low.31 Further
studies of HF therapies and cardiac devices speciﬁcally in
CKD G4þ are needed, particularly for HFpEF, which remains
the leading type of HF in patients with CKD G4þ
(Supplementary Table S4 and Table 5). Although the rates of
incident (i.e., de novo) and recurrent heart failure are reported
to be lower in PD versus HD patients,66–68 in patients with
established HF the mortality rate may be higher in PD versus
HD patients.69 This likely reﬂects confounding by indication
because frail HF patients are preferentially offered PD as it
causes less acute hemodynamic stress. Prospective clinical
trials comparing PD with HD are warranted.
Shared decision-making for kidney failure therapy
Predicting adverse outcomes after initiation of kidney
replacement therapy. Several registries70,71 and cohort
studies,6 provide population-based risks of mortality inTable 4 | Management of HF in CKD G4D
Approach Are there data in CKD G4D?
b-Blockers Yes: observational data and small
RAAS inhibitors No
MRAs Ongoing trials
Neprilysin inhibitors No
Treatment of anemia Yes
Treat mineral metabolism abnormalities Yes
Frequent dialysis Yes
Ultraﬁltration Small observational studies and t
Cardiac resynchronization therapy Small observational studies
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; HF, heart failur
system.
Kidney International (2018) -, -–-patients initiating KRT. An important observation is that
mortality rates are highest within the ﬁrst 4 months of
starting dialysis and decline in subsequent months.6 In the
DOPPS cohort, such high early mortality was observed across
countries, and differences between early and later mortality
were more pronounced among patients aged $65 years
compared with younger patients.6 Although dialysis with-
drawal accounts for some of the early mortality, it does not
provide the only explanation. CVD events are also much
higher in the ﬁrst weeks after KRT initiation.5
Studies have also demonstrated a high residual burden of
symptoms and geriatric syndromes, such as dementia and
disability, and utilization of health care among patients
commencing dialysis, especially in those who are frail, have
multiple chronic conditions, and start dialysis in the context
of a prolonged hospitalization.72–76 These outcomes are
important to patients and sometimes more so than mortality.
High early morbidity and mortality raises questions about
the potential causes and risk mitigation strategies; in partic-
ular it raises concerns that for some patients, initiation of
KRT may not be the optimal choice of therapy. Several
prognostic tools have been developed to predict short-term
mortality among patients who have initiated dialysis.77–80
Nevertheless, it is difﬁcult to predict with sufﬁcient cer-
tainty which patients will do poorly on dialysis.81
By providing quantitative estimates of the risk of KRT
initiation, CVD events, and mortality based on individual
patient characteristics, the novel CKD-G4þ risk calculator
may facilitate decision-making9 (Figure 3). For patients not
yet in kidney failure, it is also noteworthy to recognize that a
substantial proportion of CKD G4þ patients survive without
CVD events and KRTover 2- and 4-year observation periods.
Optimal counseling for treatment modality decisions.
Counseling for KRT should be risk-based, iterative, and
patient-centered. In addition, it should be tailored to the
cultural setting, health literacy, and psychosocial and
emotional needs while being mindful of the presence of
cognitive impairment. Options available once kidney failure
is expected include comprehensive conservative careLimitations for use in CKD G4D?
trials May have more adverse effects
Hyperkalemia
Risk of progressive loss of eGFR
Hyperkalemia
Risk of progressive loss of eGFR
May have higher risk of hyperkalemia
Unknown dose
May be linked with worse outcomes
Not a clear beneﬁt
Many patients cannot do home therapies, and frequent in-center
dialysis is not always available
rials May cause intradialytic hypotension and/or myocardial stunning
May have more adverse effects, such as infections
e; MRA, mineralocorticoid receptor antagonist; RAAS, renin-angiotensin-aldosterone
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Table 5 | Research recommendations for HF diagnosis and management in CKD G4D
Areas for future research Research recommendations
Screening for HF in CKD G4þ  Does screening lead to better outcomes?
 Is screening cost effective?
 What is the best way to screen for HF (e.g., imaging biomarkers)?
Deﬁnition and classiﬁcation of HF
in CKD G4þ
 What is the incidence of HFpEF versus HFrEF?
 Conduct study of the burden and outcomes associated with right ventricular dysfunction
HF risk factors  What is the relationship between residual kidney function in HD and risk of progression of subclinical
and clinical HF?
 Assess contribution of ischemic heart disease to development of HF
Outcomes related to HF in CKD G4þ  Pay speciﬁc focus on progression of CKD and initiation of dialysis
 Examine risk of other CVD subtypes and death related to HF speciﬁcally in CKD G4þ
 Conduct quality of life and other patient-reported outcome studies after dialysis initiation
Management of HF in CKD G4þ  What is the strategy for use of RAAS inhibitors, beta-blockers, MRAs, and neprilysin?
 What are point-of-care tests for kidney function, electrolytes, and surrogate markers of heart failure
(e.g., BNP)?
 What are test interventions for novel risk factors?
 Determine optimal targets for volume management
 What is the efﬁcacy of invasive and noninvasive devices for volume assessment?
 What is the efﬁcacy of mechanical circulatory support?
 What are the desirable outcomes for heart-kidney transplants?
 What is the optimal vascular access strategy?
 What is the role of urgent start PD for acute HF and CKD/AKI?
 What is the role of conservative care in this population?
AKI, acute kidney injury; BNP, B-type natriuretic peptide; CKD, chronic kidney disease; CVD, cardiovascular disease; HD, hemodialysis; HF, heart failure; HFpEF, heart failure with
preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; PD, peritoneal dialysis; RAAS, renin-angiotensin-
aldosterone system.
KDIGO execu t i ve conc lu s i ons K-U Eckardt et al.: Prognosis of advanced CKD: a KDIGO conference reportwithout dialysis, in-center or home HD, PD, and
transplantation. Circumstances may exist in which a speciﬁc
modality of KRT may be contraindicated, but when options
exist, a shared decision-making approach to the choice of
KRT optimizes patient engagement and may potentially
improve outcomes. Discussions should be revisited at
regular intervals to ensure that important health or social
circumstances have not changed.
Two scenarios require special considerations: counseling
for transplantation in older adults and counseling to forgo
dialysis. It is accepted that, among patients placed on the
waiting list, kidney transplantation improves life expectancy
and quality of life compared with those remaining on dialysis
across all age ranges.82 In and of itself, older age is not a
contraindication to transplantation.83 Although only a pro-
portion of patients will qualify for transplantation, trans-
plantation should be considered in all patients who do not
have obvious contraindications for KRT. Referral and evalu-
ation for transplantation should be based on patient charac-
teristics, preferences, and regional circumstances.84
Unwarranted regional variability in access to transplantation
is well-documented, and transplant programs should estab-
lish transparent policies for accepting patients on the waiting
list.
General counseling about KRT should also include infor-
mation about the option to forgo dialysis and receive conser-
vative care. The Renal Physicians Association has published
guidelines regarding circumstances in which forgoing dialysis
may be appropriate (Supplementary Table S8).85 Although the
beneﬁt of initiating KRT declines with increasing age,86 older
age per se should not be considered as a contraindication for
KRT; in fact, conference participants questioned the Renal8Physicians Association recommendation to generally forgo
dialysis in patients$75 years with poor prognosis and favored a
more individualized approach, taking into account patient
preferences and values along with prognosis.
Uncertainties about initiation of kidney replacement therapies
and research priorities. A recent meta-analysis of cohort
studies and trials has demonstrated that those who
commence dialysis with a higher eGFR have a higher
mortality.87 It is likely that this is due to reverse causality,
with frailty and accumulated comorbidities, in particular HF,
pushing the patient and clinician to initiate dialysis. Global
differences exist in how planned KRT is initiated. These
include a “PD ﬁrst” approach, commencement with a
functioning arteriovenous ﬁstula and differences in site of
ﬁstula placement and “incremental” start to dialysis with
either reduced blood ﬂow rates, reduced hours, or limited
PD exchanges. To which extent these factors inﬂuence
outcomes is largely unclear. The indication for initiation of
dialysis should be recorded routinely in registry data in
addition to reporting elective versus unplanned start to
dialysis. In the IDEAL study the majority of patients allocated
to late start who started early had the indication for start
identiﬁed as “uremia.”88 Hence, it would be useful to
understand the spectrum of symptoms that prompted
initiation of dialysis to provide greater clarity regarding the
optimum commencement. Research recommendations are
summarized in Table 6.
Needs, opportunities, and challenges for clinical trials in
patients with CKD G4D
Barriers for clinical trials in patients with CKD G4þ and
strategies to overcome them. There is an urgent need toKidney International (2018) -, -–-
Table 6 | Research recommendations for shared decision-
making for KRT
 Assess optimal ways to deliver information to people and families with
CKD
 Does provision of prognostic data alter decision-making?
 What are the reasons for variation in acceptance onto dialysis or
transplantation programs?
 Why is morbidity and mortality high in the ﬁrst 3 months of
commencing hemodialysis, and can it be modiﬁed?
 Is there an optimal approach to the commencement of dialysis to
reduce morbidity and mortality?
 Can comorbidity be factored into the reporting of kidney outcomes?
 Place greater emphasis on collection of patient-centered KRT outcomes,
including quality of life, symptom burden, physical and cognitive
function, and ﬁnancial and caregiver burdens
 Can the reasons for commencing dialysis be uniformly collected to
improve the understanding of variability in the timing of initiation of
dialysis?
CKD, chronic kidney disease; KRT, kidney replacement therapy.
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patients with CKD, including people with CKD G4þ
(Supplementary Table S9).89,90 A summary of selected bar-
riers and proposed solutions is shown in Table 7 and
Supplementary Table S10. For industry, the potential eco-
nomic beneﬁts of a successful clinical trial must be offset
against the potential ﬁnancial and nonﬁnancial risks. Slow
recruitment, higher-than-average adverse event rates, a rela-
tively small total patient population (i.e., prospective users),
and several recent null clinical trials in CKD populations may
all increase perceived risk. However, trials in populations with
CKD G4þ also have key advantages, including the large po-
tential economic beneﬁts of preventing kidney failure and
CVD events, a relatively captive and highly motivated patient
population, and high event rates (reducing the required
sample size or duration of follow-up).
Investigator-initiated trials have different challenges: the
nephrology community understands the clinical need andTable 7 | Research recommendations for enhancing clinical
trials in CKD G4D
1. Develop systems to systematically monitor the quantity and quality of
clinical trials in nephrology. Output of these monitoring services could
be linked to ongoing updates of KDIGO guidelines.
2. Develop new or reﬁne existing clinical trial designs to optimize success
rates for clinical trials including enrichment trials, pragmatic trials, or
platform trials.
3. Continue to conduct trials on interventions to slow the progressive loss
of kidney function and to safely defer the initiation of dialysis.
4. Develop other trial end points that are transferable globally and more
aligned to patient research priorities, such as preserving functional
status and cognition and reducing infections.
5. Deﬁne which end points are relevant for different patient groups; for
example, mortality, access to kidney transplantation, and availability to
continue to work for younger patients, and delaying initiation of dial-
ysis, avoiding hospitalizations, and living independently for older
patients.
6. Conduct clinical trials in which patients are followed beyond dialysis
initiation and/or transplantation.
CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes.
Kidney International (2018) -, -–-opportunities in the CKD G4þ population but often struggles
to complete adequately powered studies.91 Environmental
scans of ongoing trials suggest that certain topics
(e.g., sodium bicarbonate treatment in CKD G4þ) are being
independently studied by multiple groups in different coun-
tries. One potential solution could be to link multiple existing
national trial networks to increase statistical power, either by
use of common protocols or by pooling results from similar
but not identical protocols using meta-analysis.92
Choosing patient-relevant interventions and outcomes. As
for most medical disciplines, available trial evidence in CKD
G4þ populations reﬂects the interests and priorities of
clinicians and researchers rather than patients and families.
Correcting this misalignment is critical for improving the
utility of trial ﬁndings and potentially for facilitating trial
conduct by increasing participant recruitment and retention.
Existing processes for identifying patient-centered research
priorities and patient-relevant outcomes (e.g., those
identiﬁed using the James Lind Alliance methodology) will
be helpful for achieving this aim. A list of such priorities for
CKD G3a to G5 patients is already available93,94 and could
be used as the basis for people with CKD G4þ speciﬁcally.
Initiation of KRT is clinically meaningful and, therefore, the
obvious choice as an outcome in trials of therapies aimed at
slowing the loss of kidney function. However, KRT initiation
is determined by many factors such as local habits and
guidelines, physicians’ and patients’ preferences, and
patients’ well-being and comorbidities. Functional and
symptomatic outcomes that are patient-oriented, both
before and after the initiation of KRT, are important to
address for safety as well as efﬁcacy, and are relevant for the
patient. A toolbox that includes validated symptomatic
assessment will support trials with functional outcomes.
Increasing and sustaining patient engagement in trials and
other clinical research is critical, but no consensus was
reached on how this goal should be achieved or approached.
A key starting point could be to describe lessons learned from
leading patient-centered initiatives (e.g., SONG-HD95 and
NICE) and establish an organization responsible for patient
engagement in CKD G4þ research speciﬁcally.
Increasing the success of clinical trials in CKD G4þ by
optimizing other aspects of trial design. Besides outcomes,
other aspects of clinical trial design could be optimized. Thus,
the KFRE and the newly developed predictive instrument
speciﬁc for CKD G4þ could be used in potential trial partici-
pants to inform power calculations or enrich recruitment of
participants at higher-than-average risk.11 Alternative methods
(e.g., pragmatic trials, stepped-wedge designs, or registry-
based studies) could also be used to facilitate trial conduct.96
Pragmatic trials are well suited for patients with CKD G4þ
because such trials can enroll socially disadvantaged
populations (usually excluded from traditional randomized
controlled trials), are directly applicable to patient care, allow
assessment of a range of interventions, include patient-
centered outcomes, and are cheaper than traditional
randomized controlled trials. There are also some challenges,9
KDIGO execu t i ve conc lu s i ons K-U Eckardt et al.: Prognosis of advanced CKD: a KDIGO conference reportsuch as lack of experience, collection and ascertainment of
outcomes, and informed consent procedure, which may pose
challenges given the increasing use of electronic health records.
Conclusions and perspectives
Patients with CKD G4þ represent a high-risk population that
requires specialized care and expertise that should ideally be
coordinated by nephrologists. Despite their severely reduced
level of GFR, the prognosis of patients with CKD G4þ is
variable, with a substantial proportion of up to more than
50% surviving CVD event- and KRT-free for at least several
years. The newly developed risk prediction tool speciﬁc for
CKD G4þmay help to establish a comprehensive quantitative
analysis of possible adverse outcomes, including CVD events,
kidney failure and mortality, and thereby guide therapy. Such
prognostic information can be factored into decisions for
surveillance, CVD risk reduction, and eventual preparation
for KRT. Another important ﬁnding of the meta-analysis is
that traditional CVD risk factors appear to be relevant in
CKD G4þ, like in earlier stages of CKD and in the absence of
CKD. Although such associations do not prove the efﬁcacy of
risk factor targeting, it appears rational to apply such strate-
gies as long as no opposing evidence is available. Finally, there
was general agreement that the complex comorbidities of
people with CKD G4þ, particularly those with functional
impairment, older age, and limited life expectancy, mandate a
patient-centric approach with joint decision-making both in
routine practice as well as during the design of trials to
optimize management and outcomes.
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